TAIWAN BIO THERAPEUTICS CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.15 TWD | -.--% |
|
-1.42% | +11.22% |
More news
| 1 week | -1.42% | ||
| 1 month | +1.87% | ||
| 3 months | +12.04% | ||
| 6 months | +11.88% | ||
| Current year | +11.22% |
1 week
37.55
38.45
1 month
36.3539.10
Current year
32.6040.15
1 year
31.1040.15
3 years
26.3550.50
5 years
26.3550.50
10 years
26.3550.50
| Managers | Title | Age | Since |
|---|---|---|---|
Hung Pin Chen
CEO | Chief Executive Officer | - | 18-06-14 |
| Director of Finance/CFO | - | 21-11-30 | |
Chun Yao Yang
COO | Chief Operating Officer | - | 18-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chung Liang Li
BRD | Director/Board Member | 71 | 21-06-23 |
Wan Ya Chang
BRD | Director/Board Member | - | 15-06-15 |
Chih Yuan Huang
CHM | Chairman | - | 17-06-15 |
Taiwan Bio Therapeutics Co Ltd is a Taiwan-based company mainly engaged in the development of new allogeneic stem cell drugs and the provision of contract development and manufacturing organization (CDMO) services. The main products include Chondrochymal for the treatment of degenerative arthritis of the knee, Biochymal for the treatment of difficult non-healing wounds caused by lower extremity ischemia, OmniMSC/TBPCB201 for the treatment of acute myocardial infarction, and MSC-VEGF for the treatment of lower extremity ischemia. The cell processing center (CPC) is engaged in the provision of a full set of CDMO services, process scale-up services, inspection and development services, and quality control commissioned inspection services. The Company mainly operates in Taiwan market.
| 1st Jan change | Capi. | |
|---|---|---|
| +11.22% | 59.61M | |
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- 6892 Stock
